Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. Pharvaris aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated and easy-to-administer alternatives to treat attacks.
Products, services, technology
Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable prophylactic treatment, and an immediate-release capsule to enable on-demand treatment.
- https://pharvaris.com/
- +41 41 561 42 00
- info@pharvaris.com
- Maggie Beller
